Seraxis and Sernova Announce Appointment of Former FDA Medical Officer Dr. Patricia Beaston as Chief Medical Officer of Seraxis and Post Merger BetaNova Biotherapeutics
Seraxis and Sernova (OTC: SEOVF) appointed Dr. Patricia Beaston, a former FDA Medical Officer with 24 years of agency experience, as Chief Medical Officer of Seraxis, with the same role at the proposed combined company BetaNova Biotherapeutics. Her FDA background spans islet cell transplantation, immune modulation in type 1 diabetes, and cell and gene therapies at CBER, directly relevant as SR-02 enters a Phase 1/2 trial with first patient dosing targeted for Q1 2027 following IND clearance.
Key figures
- Fda tenure years
- 24
- Sr03 ind submission target
- second half of 2027
- Sr02 first patient dosing target
- Q1 2027
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.